Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab vs Vedolizumab Stratified by Geboes Score in UC
NCT06626165Phase 4Completed
- Sponsor
- Showa Inan General Hospital
- Start
- Jul 2024
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of mirikizumab in ulcerative colitis (UC) (2 arms), sponsored by Showa Inan General Hospital. Primary endpoint: Changes in clinical activities at 2 weeks. Started Jul 2024; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06626165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06626165.